207 related articles for article (PubMed ID: 36627512)
21. Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics.
Chen JC; King OD; Zhang Y; Clayton NP; Spencer C; Wentworth BM; Emerson CP; Wagner KR
Mol Ther; 2016 Aug; 24(8):1405-11. PubMed ID: 27378237
[TBL] [Abstract][Full Text] [Related]
22. Facioscapulohumeral muscular dystrophy.
Tawil R
Handb Clin Neurol; 2018; 148():541-548. PubMed ID: 29478599
[TBL] [Abstract][Full Text] [Related]
23. Protein kinase A activation inhibits
Cruz JM; Hupper N; Wilson LS; Concannon JB; Wang Y; Oberhauser B; Patora-Komisarska K; Zhang Y; Glass DJ; Trendelenburg AU; Clarke BA
J Biol Chem; 2018 Jul; 293(30):11837-11849. PubMed ID: 29899111
[TBL] [Abstract][Full Text] [Related]
24. Control of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Cancer.
Karpukhina A; Tiukacheva E; Dib C; Vassetzky YS
Trends Mol Med; 2021 Jun; 27(6):588-601. PubMed ID: 33863674
[TBL] [Abstract][Full Text] [Related]
25. p38
Rojas LA; Valentine E; Accorsi A; Maglio J; Shen N; Robertson A; Kazmirski S; Rahl P; Tawil R; Cadavid D; Thompson LA; Ronco L; Chang AN; Cacace AM; Wallace O
J Pharmacol Exp Ther; 2020 Sep; 374(3):489-498. PubMed ID: 32576599
[TBL] [Abstract][Full Text] [Related]
26. RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy.
Wallace LM; Liu J; Domire JS; Garwick-Coppens SE; Guckes SM; Mendell JR; Flanigan KM; Harper SQ
Mol Ther; 2012 Jul; 20(7):1417-23. PubMed ID: 22508491
[TBL] [Abstract][Full Text] [Related]
27. Facioscapulohumeral muscular dystrophy type 2: an update on the clinical, genetic, and molecular findings.
Jia FF; Drew AP; Nicholson GA; Corbett A; Kumar KR
Neuromuscul Disord; 2021 Nov; 31(11):1101-1112. PubMed ID: 34711481
[TBL] [Abstract][Full Text] [Related]
28. Muscle eosinophilia is a hallmark of chronic disease in facioscapulohumeral muscular dystrophy.
Nunes AM; Ramirez MM; Garcia-Collazo E; Jones TI; Jones PL
Hum Mol Genet; 2024 May; 33(10):872-883. PubMed ID: 38340007
[TBL] [Abstract][Full Text] [Related]
29. A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy.
Feng Q; Snider L; Jagannathan S; Tawil R; van der Maarel SM; Tapscott SJ; Bradley RK
Elife; 2015 Jan; 4():. PubMed ID: 25564732
[TBL] [Abstract][Full Text] [Related]
30. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.
Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL
Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623
[TBL] [Abstract][Full Text] [Related]
31. PAX7 target gene repression associates with FSHD progression and pathology over 1 year.
Banerji CRS
Hum Mol Genet; 2020 Aug; 29(13):2124-2133. PubMed ID: 32347924
[TBL] [Abstract][Full Text] [Related]
32. Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy.
Bittel AJ; Sreetama SC; Bittel DC; Horn A; Novak JS; Yokota T; Zhang A; Maruyama R; Rowel Q Lim K; Jaiswal JK; Chen YW
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759720
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy.
Cohen J; DeSimone A; Lek M; Lek A
Trends Mol Med; 2021 Feb; 27(2):123-137. PubMed ID: 33092966
[TBL] [Abstract][Full Text] [Related]
34. Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers.
van den Heuvel A; Lassche S; Mul K; Greco A; San León Granado D; Heerschap A; Küsters B; Tapscott SJ; Voermans NC; van Engelen BGM; van der Maarel SM
Sci Rep; 2022 Jan; 12(1):1426. PubMed ID: 35082321
[TBL] [Abstract][Full Text] [Related]
35. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.
Gatica LV; Rosa AL
Neuromuscul Disord; 2016 Dec; 26(12):844-852. PubMed ID: 27816329
[TBL] [Abstract][Full Text] [Related]
36. Intrinsic epigenetic regulation of the D4Z4 macrosatellite repeat in a transgenic mouse model for FSHD.
Krom YD; Thijssen PE; Young JM; den Hamer B; Balog J; Yao Z; Maves L; Snider L; Knopp P; Zammit PS; Rijkers T; van Engelen BG; Padberg GW; Frants RR; Tawil R; Tapscott SJ; van der Maarel SM
PLoS Genet; 2013 Apr; 9(4):e1003415. PubMed ID: 23593020
[TBL] [Abstract][Full Text] [Related]
37. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
[TBL] [Abstract][Full Text] [Related]
38. Current Therapeutic Approaches in FSHD.
Wang LH; Tawil R
J Neuromuscul Dis; 2021; 8(3):441-451. PubMed ID: 33579868
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of
Lim KRQ; Maruyama R; Echigoya Y; Nguyen Q; Zhang A; Khawaja H; Sen Chandra S; Jones T; Jones P; Chen YW; Yokota T
Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16509-16515. PubMed ID: 32601200
[TBL] [Abstract][Full Text] [Related]
40. Knocking Down DUX4 in Immortalized Facioscapulohumeral Muscular Dystrophy Patient-Derived Muscle Cells.
Lim KRQ; Yokota T
Methods Mol Biol; 2023; 2587():197-208. PubMed ID: 36401032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
